A phase 2 exploratory study of NS-304 in Japanese pediatric patients with pulmonary arterial hypertension
Latest Information Update: 24 Aug 2022
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Nippon Shinyaku
- 23 Aug 2022 Planned End Date changed from 30 Jun 2022 to 30 Nov 2025.
- 23 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 07 Jan 2022 New trial record